Campylobacter jejuni is one of the most common enterocolitis-causing microorganisms worldwide. It is of particular importance in immunodeficient patients, who frequently are prone to develop extraintestinal manifestations. Since these cases respond poorly to antibiotic treatment, a supportive immunomodulating therapy including the administration of C. jejuni-specific immunoglobulins would be desirable. In the present study, nine commercial immunoglobulin preparations for intravenous use were tested for the presence of C. jejuni lipopolysaccharide (LPS)-and outer membrane protein (OMP)-specific antibodies by using immunoblot and enzyme-linked immunosorbent assay techniques. The immunoglobulin G (IgG) antibody reactivities against these antigens were comparable in eight of nine tested immunoglobulin preparations. Only in one preparation were C. jejuni OMP-and LPS-specific IgM antibodies found. In this preparation the immunoblot test revealed a strong reactivity against both flagellin and a major OMP. Moreover, all immunoglobulin preparations recognized OMPs of C. jejuni serotypes Lior 4, 9, 11, and 29 equally strongly, while the reactivity to an anti-Lior 36 isolate was less marked. Furthermore, the bactericidal properties of three immunoglobulin preparations were tested by means of chemiluminescence signaling in and bacterial killing by human polymorphonuclear leukocytes (PMNL). The results show that the IgM preparation enhanced Campylobacter-triggered chemiluminescence signaling in PMNL as well as killing of C. jejuni by PMNL, while the other immunoglobulin preparations did not do so. These results suggest that the administration of immunoglobulin preparations containing C. jejuni-specific IgM antibodies would be beneficial for patients with severe C. jejuni infections.
Campylobacter jejuni is one of the most frequently observed microbial pathogens in enteritis and enterocolitis in humans worldwide (7) . Although C. jejuni infections are generally selflimiting, extraintestinal manifestations, including skin lesions, as well as chronic persistent infections can occur, particularly in groups at high risk (e.g., patients with hypogammaglobulinemia, previous radiation therapy, or chronic renal failure) (6, 8, 15) . Moreover, sequelae such as reactive arthritis and Reiter's syndrome are associated with intestinal C. jejuni infections (6) . Of particular concern is Guillain-Barré syndrome (GBS), which has been linked to C. jejuni infection very recently (10, 12) . Peracute progressive forms of GBS which may extend to bulbar palsy likewise appeared to be associated with C. jejuni infection (10, 12) .
In addition to symptomatic treatment, antibiotic therapy with, e.g., erythromycin is recommended for C. jejuni infections (29) . However, resistance of C. jejuni to erythromycin (7.3% of strains) or doxycycline (12.4% of strains) has been reported (29) . In addition, antibiotic treatment neither shortens the period of diarrhea nor prevents severe complications such as GBS (30) . Therefore, other therapeutic approaches, including adjuvant immunomodulating therapy, would be desirable for these patients.
The host mechanisms involved in overcoming C. jejuni infections are not yet well understood. However, there is evidence that the presence of C. jejuni-specific antibodies is associated with resistance to clinical disease, while colonization of the intestine with C. jejuni is not affected (4, 5) . In an experimental mouse infection model it was shown that the oral administration of cytokines such as interleukin-2, -5, or -6 modulates mucosal immunity against, and thus may have some effect on the colonization of the intestine with C. jejuni (2) . However, the results of this study are not clear-cut, and this approach is far from being considered clinically relevant. Moreover, the therapeutic administration of cytokines has a number of side effects, such as toxicity, and is very expensive.
A recent report provided evidence that the intravenous administration of an immunoglobulin preparation containing immunoglobulin M (IgM) antibodies may be beneficial for immunocompromised patients suffering from persistent C. jejuni infection which does not respond to therapy with antibiotics (8) . Moreover, oral administration of IgA was successful in the treatment of refractory C. jejuni infection in an immunocompromised patient (13) . Therefore, in order to evaluate systematically the potential value of various immunoglobulin preparations in the therapy of C. jejuni infections, we tested the specificities and immunobiological properties of different commercially available products. Here we report on the presence of C. jejuni lipopolysaccharide (LPS)-and outer membrane protein (OMP)-specific IgG and IgM antibodies in these preparations as determined by enzyme-linked immunosorbent assay (ELISA) and immunoblotting. Furthermore, the immunobiological properties of immunoglobulin preparations in terms of mediation of chemiluminescence (CL) signaling in and killing of C. jejuni by human polymorphonuclear leukocytes (PMNL) are analyzed.
MATERIALS AND METHODS
Bacterial strains. C. jejuni strains of the Lior 4, 9, 11, 29 , and 36 serotypes were kindly provided by J. Bockemühl (German Reference Center for Enterobacteriaceae, Hamburg, Germany). These strains and serotypes were selected because they are the ones most frequently found in patients with Campylobacter infections in Germany (10, 32 Isolation of OMPs. One hundred milliliters of a bacterial suspension of approximately 4 ϫ 10 5 microorganisms (C. jejuni Lior 4, 9, 11, 29, or 36) per ml was centrifuged at 4,000 ϫ g for 15 min. The pellet was resuspended in 10 ml of a 10 mM Tris-HCl buffer (pH 8.0) and sonicated (four times for 30 s at level 3; 4ЊC) with a B15 sonicator (Branson, Danbury, Conn.). Intact cells were separated by centrifugation (1,475 ϫ g, 20 min, 4ЊC). The resulting pellet was centrifuged again (48,200 ϫ g, 60 min, 4ЊC) and then resuspended in 150 l of deionized water and titrated with an eightfold volume of 1.67% (wt/vol) N-lauroyl-sarkosine (Sigma, Deisenhofen, Germany) in 11.1 mM Tris-HCl (pH 7.6). The cytoplasmic proteins were extracted over 20 min at room temperature. The sediment (OMPs) was then harvested by centrifugation (46,000 ϫ g, 90 min, 20ЊC); the pellet was resuspended in 500 l of deionized water and kept at Ϫ20ЊC until used.
Extraction of LPS. LPS from C. jejuni Lior 11 was extracted with phenol-water. Three hundred milliliters of a bacterial suspension with a microorganism layer of 10 5 cells per ml was centrifuged (4,000 ϫ g, 15 min), and the pellet was then resuspended in 20 ml of warm deionized water at 68 to 70ЊC. The bacterial suspension was then titrated with 20 ml of warm 90% phenol at 68ЊC and, after stirring, incubated for 20 min in a water bath at 68ЊC. Finally, the suspension was centrifuged for 15 min at 2,600 ϫ g and room temperature, and the upper aqueous phase was carefully drawn off with a pipette. Further processing was performed as described by Karch et al. (14) .
Immunoglobulin preparations used. The following commercially available immunoglobulin preparations were used: Sandoglobulin (Sandoz AG, Nürnberg, Germany), Gammagard (Baxter Deutschland GmbH, Unterschleissheim, Germany), Polyglobin N (Tropon-Werke GmbH & Co., KG, Köln, Germany), Venimmun (Behring-Werke, Marburg, Germany), Endobulin (Immuno, Heidelberg, Germany), Gammonativ N (Kabi Pharmacia GmbH, Erlangen, Germany) Purimmun (Armour Pharma GmbH, Eschwege, Germany), and Intraglobin and Pentaglobin (Biotest Pharma GmbH, Dreieich, Germany). All preparations were dissolved by using the accompanying solvent buffer according to the manufacturers instructions or, in the case of ready-for-use preparations, were diluted in PBS buffer to provide a constant immunoglobulin concentration of 50 mg/ml in all the test solutions.
ELISA. The antigen preparations used for coating microtiter plates (Greiner, Frickenhausen, Germany) contained 1 g of OMP or freeze-dried LPS preparation from C. jejuni of serotype Lior 4, 9, 11, 29,  (31). Anti-human IgG or anti-human IgM alkaline phosphatase conjugates (Dianova, Hamburg, Germany) diluted 1:2000 were used as secondary antibodies. Extinction phases (optical densities) were determined photometrically at 492 nm with an ELISA reader (Titertec Multiscan MCC 340; Flow Laboratories, Irvine, Calif.). Each test was done three times, and the mean values were calculated. The cutoff was defined as the mean absorbance of controls (campylobacter-negative pooled human sera) plus two standard deviations.
Immunoblot analysis. The OMPs were separated in 12% sodium dodecyl sulfate (SDS)-polyacrylamide gels and transferred onto nitrocellulose by Western blotting (immunoblotting) as described previously (10) . For the detection of IgG antibodies, the immunoglobulin preparations were diluted to 1:100, 1:200, and serially up to 1:12,800 with PBS containing 0.5% Tween 20. For the determination of IgM antibodies, dilution ratios of 1:12.5 and serially up to 1:400 were selected. The 2-mm-wide nitrocellulose strips were incubated overnight at room temperature. After three washes with 0.5% Tween 20 in PBS, they were incubated with polyclonal goat anti-human IgG or IgM (1:1,000 in PBS with 0.5% Tween 20) for 4 h at room temperature. The development of the blot strips was carried out as described elsewhere (10) .
Preparation of human PMNL. PMNL were isolated from blood taken either from healthy volunteers or from a patient with hypogammaglobulinemia and persistent C. jejuni infection as described recently (11) . Briefly, heparinized blood was layered on Mono-Poly-Resolving medium (Flow Laboratories) and centrifuged for 40 min at 22ЊC and 400 ϫ g. The resulting lower layer, which contained the PMNL, was harvested and washed in HEPES (N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid) (10 mM)-buffered Geys solution (pH 7.4) or PBS buffer. Purified PMNL were finally suspended in 1 ml of assay medium, counted, and adjusted to the desired concentration. The viability of the cells was more than 98% as determined by trypan blue dye exclusion.
CL measurements. Luminol-amplified CL responses of PMNL were measured with a microplate chemiluminometer (Hamamatsu Photonics, Herrsching, Germany) at 37ЊC as previously described (11) . PMNL (10 5 per microtiter plate well) were incubated for 2 h at 37ЊC in RPMI 1640 cell culture medium (Biochrom, Berlin, Germany) containing 2.5 ϫ 10 Ϫ5 M luminol (Sigma) and 5% serum from a patient with hypogammaglobulinemia. To parallel wells, 50-mg portions of the immunoglobulin preparations mentioned above were added. For stimulation of PMNL, 10 7 cells of C. jejuni were added to the wells. Control wells contained luminol, serum, and medium only. Light emission was recorded continuously for 90 min, and the total amount of light emission was calculated from the sum of the counts of 30-s intervals. Values shown are the means from triplicate wells. All experiments were done at least three times and showed comparable results.
Bactericidal assays. The bactericidal assay was performed as previously described (11) . A total of 10 5 PMNL per ml were incubated with 4 ϫ 10 6 cells of C. jejuni in RPMI 1640 cell culture medium containing 10% sera from the above-mentioned donors. Parallel samples also contained 50 g of immunoglobulin preparations per ml. After 30 min, the cells were washed to remove extracellular bacteria, and after 2 h of incubation with 50 g of gentamicin per ml, the PMNL were washed and then lysed by resuspension in PBS buffer containing 0.1% bovine serum albumin and 0.5% tergitol type TMN 10 (Sigma). Duplicates of 0.1-ml portions of serial dilutions of this suspension were then plated on VL agar and incubated for 48 h at 41ЊC as described above, and CFU were counted.
Statistical analysis. Differences between mean values were analyzed with Student's t test. A P value of Ͻ0.05 was considered statistically significant.
RESULTS

Anti-C. jejuni IgG antibodies in immunoglobulin preparations.
The presence of C. jejuni-specific IgG antibodies in the immunoglobulin preparations was determined by both ELISA and immunoblot procedures. Analysis of the immunoglobulin preparations by ELISA revealed significant and similar IgG reactivities to OMPs of C. jejuni serotypes Lior 4, 9, 11, 29, and 36 in all samples tested. The data for C. jejuni Lior 11 are depicted in Fig. 1 . Comparable results were found when the LPS preparation from C. jejuni Lior 11 was used as an antigen (data not shown). However, because of the low IgG content, the IgM preparation (Pentaglobin) showed a weaker reactivity (Fig. 1) . In the IgG immunoblot analysis including OMPs of C. jejuni of various serotypes, all immunoglobulin preparations up to a dilution of 1:800 exhibited reactivity, with four to six protein bands with molecular masses in the range of 20 to 95 kDa. A representative immunoblot analysis for OMPs of C. jejuni Lior 11 is shown in Fig. 2a . Thus, we can conclude that all immunoglobulin preparations tested contained IgG antibodies directed against both OMPs and LPS of C. jejuni. Anti-C. jejuni IgM antibodies in immunoglobulin preparations. As described above, the presence of C. jejuni-specific IgM antibodies in the immunoglobulin preparations was determined by ELISA as well as by immunoblot procedures. In only one immunoglobulin preparation (Pentaglobin) was a significant level of IgM antibody specific for all C. jejuni serotypes tested observed. Figure 1 displays the reactivities of the immunoglobulin preparations, measured by ELISA, with C. jejuni Lior 11 OMPs as an antigen. Comparable results were found for LPS of C. jejuni Lior 11 (data not shown). Hence, only in Pentaglobin were C. jejuni LPS-specific IgM antibodies found. Likewise, only in this immunoglobulin preparation was a clearcut band spectrum apparent in the immunoblot analysis (with OMPs of C. jejuni Lior 11) up to a dilution of 1:800 (Fig. 2b) . Antibody reactivity against protein bands at approximately 40 and 60 kDa was particularly noticeable (Fig. 2b ). These results demonstrate that C. jejuni OMP-and LPS-specific IgM antibodies are present in only one immunoglobulin preparation (Pentaglobin).
Reactivities of immunoglobulin preparations against various serotypes of C. jejuni. The reactivities of the immunoglobulin preparations against OMPs of different serotypes of C.
jejuni were assessed by immunoblot analysis. Figure 3 shows that Pentaglobin reacted strongly with C. jejuni Lior 4, 9, 11, and 29, whereas the reaction against serotype Lior 36 was less prominent. The results for the other immunoglobulin preparations were similar (data not shown).
In the spectrum of IgM antibodies detected (Pentaglobin only), the bands with molecular masses of approximately 60 kDa were most prominent. As shown with rabbit anti-C. jejuni flagellin antibodies, these bands could be identified as flagellin. Likewise, a protein band of 90 kDa which was reactive with the IgM preparation (Fig. 3, lane 2) was also recognized by the rabbit antiflagellin serum (data not shown).
Immunobiological properties of immunoglobulin preparations. In order to evaluate the immunobiological properties of the immunoglobulin preparations, their effects on luminolamplified CL responses of human PMNL triggered by C. jejuni as well as on killing of C. jejuni by PMNL were investigated. For this purpose, PMNL were incubated with C. jejuni in the presence of serum from a patient with hypogammaglobulinemia, and various immunoglobulin preparations were added to parallel samples. The data depicted in Fig. 4 indicate that C. jejuni-triggered CL responses of PMNL were significantly enhanced by the IgM immunoglobulin preparation (Pentaglobin), to 32.1% (P Ͻ 0.05 compared with the controls), while the other immunoglobulin preparations tested did not exhibit a significant effect on CL signaling. In keeping with these results, the killing of C. jejuni by PMNL was increased only in the presence of the IgM immunoglobulin preparation and not with the other immunoglobulin preparations tested. Hence, the bacterial numbers were reduced to 70.3% (P Ͻ 0.02) by Pentaglobin, while the other preparations did not exhibit a bactericidal effect on C. jejuni (Fig. 5) . Comparable results were found for the PMNL from different donors. These results suggest that only immunoglobulin preparations containing C. jejuni-specific IgM antibodies mediate bactericidal functions of human PMNL. VOL. 39, 1995 BACTERICIDAL C. JEJUNI-SPECIFIC IgM ANTIBODIESDISCUSSION C. jejuni infections are a frequent cause of diarrhea and chronic or relapsing infections, particularly in immunodeficient individuals (6) (7) (8) 13 ). For patients with common variable immunodeficiency syndrome, C. jejuni is isolated and identified as a causal organism in 5 to 10% of the cases (6, 8) . In patients without any severe underlying disease, C. jejuni infections are usually self-limiting, and only in rare cases does tissue invasion by C. jejuni occur (6, 8) .
Antibiotic treatment of C. jejuni infections and related sequelae may be totally unsuccessful, especially in immunodeficient patients (6, 8, 13) . The attempt to find adjuvant immunomodulating treatments for refractory or progressive C. jejuni infections is therefore of particular clinical interest and led us to investigate the presence and biological properties of C. jejuni-specific antibodies in commercially available immunoglobulin preparations. The most salient observation of this study was that all immunoglobulin preparations tested contained IgG antibodies directed against LPS as well as OMPs of C. jejuni. However, only one immunoglobulin preparation (Pentaglobin), which also contained IgM antibodies, mediated a significant enhancement of C. jejuni-triggered production of reactive oxygen metabolites of, as well as killing of C. jejuni by, human PMNL.
The findings from our study correspond to the clinical observations reported by Borleffs et al. (8) that clinical signs and symptoms of patients with persistent C. jejuni infection did not show any abatement despite a combination therapy involving antibiotics and intravenously administered IgG preparations. However, after Pentaglobin (IgM preparation) treatment, the pathogen was completely eliminated. The results presented here demonstrate anti-C. jejuni LPS, flagellin, and OMP reactivities in the IgM fraction of Pentaglobin. By immunoblotting, a strong IgM reactivity of Pentaglobin against proteins of C. jejuni with molecular masses of 62 to 64 kDa was observed. As shown with rabbit antiflagellin antibodies, these protein bands represent the flagellin of C. jejuni. This flagellin has been reported to have a molecular mass of 62 kDa, but its molecular mass and amino acid composition vary among different Campylobacter strains (24) . Furthermore, there is evidence that the recognized band with a molecular mass of 92 kDa is identical to the flagellar hook protein of C. jejuni as described by Power et al. (28) . Studies on the pathogenesis of C. jejuni infections have shown a dominant role for flagellin in intestinal colonization of patients (1) . Moreover, the flagellin protein is an immunodominant antigen during C. jejuni infections (1, 23) . In line with these observations, it was reported that protection against C. jejuni may be associated with the presence of antiflagellin antibodies (1, 3, 20, 26) .
C. jejuni isolates are typed either in terms of their O antigens, as described by Penner and Hennessy (27) , or in terms of heat-labile antigens comprising structures on the somatic surface of the organism, as described by Lior et al. (18) . In this context, the association between certain serotypes of C. jejuni and different clinical manifestations of C. jejuni infection, as well as the occurrence of at least three different pathogenic groups of C. jejuni, is noteworthy (10, 12, 17, 32) . In Germany, C. jejuni Lior 4 is frequently found in stool samples from patients with uncomplicated enteritis, while infection with C. jejuni Lior 11 is linked to GBS (10, 32) . In addition, enterotoxic, cytotoxic, and invasive strains have been demonstrated within the species (17, 19, 21) . In this respect, we are currently investigating to what extent immunoglobulin preparations are able to neutralize the putative virulence factors of the various pathogenic groups. These studies may contribute to a better understanding of their mechanism of action.
Although the host defense mechanisms that are required for the resolution of C. jejuni infections are not yet completely understood, our observations may serve as a possible explanation for the therapeutic efficacy of an IgM preparation in patients, as reported by Borleffs et al. (8) , and the inefficacy of IgG preparations in the same patients. Moreover, in sera obtained by immunization of rabbits with Salmonella minnesota, only the IgM fraction, and not the IgG fraction, mediated protection against this pathogen (22) . Therapeutic immunoglobulin preparations are produced from at least 1,000 individual serum donations. By therapeutic administration of these preparations, the natural polyclonal immune defense mechanisms of the hosts may be enhanced. In general, IgM antibodies play an important role in the host defense against bacterial infections (25) . The pentameric structure of IgM molecules causes about a 100-fold agglutination potency due the concen- tration of specific Fab portions. Moreover, activation of the complement system is nearly 200 times more efficient than that with IgG molecules (9, 25) .
In keeping with these characteristics, we found that the immunoglobulin preparation which contained C. jejuni-specific IgM antibodies (Pentaglobin) enhanced the bactericidal properties of human PMNL against C. jejuni, while the immunoglobulin preparations which contained only IgG did not do so. Hence, CL signaling in PMNL upon stimulation with C. jejuni was enhanced only by Pentaglobin. Although the role of reactive oxygen intermediates in killing of C. jejuni has not yet been established, this observation correlated closely with increased killing of C. jejuni by PMNL in the presence of Pentaglobin. In a number of other microbial pathogens, however, toxicity of reactive oxygen metabolites produced and released during the interaction of PMNL with microbial pathogens, including Mycoplasma, Chlamydia, Mycobacterium, and Legionella spp., has been reported (16) .
Taken together, our results provide the first direct evidence that specific IgM antibodies mediate killing of C. jejuni by PMNL. Thus, the administration of specific IgM preparations may be beneficial in (immunocompromised) patients with severe C. jejuni infections. Whether cytokines, administered either alone, as has been reported for an experimental infection model (2) , or in combination with immunoglobulins, are worthwhile in the treatment of these patients remains to be elucidated.
